JPRN-UMIN000033574
Completed
Phase 2
A validation study of biomarkers to predict responders to non-pharmacological multimodal program for advanced cancers - NEXTAC-Three
Department of Respirology, Kyoto Prefectual University of Medicine0 sites80 target enrollmentMarch 31, 2019
Conditionson-small-cell lung and pancreatic cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- on-small-cell lung and pancreatic cancer
- Sponsor
- Department of Respirology, Kyoto Prefectual University of Medicine
- Enrollment
- 80
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Having disabilities according to the modified KATZ index 2\) Having high risks for safe physical assessments and interventions (e.g. Unstable cardiac diseases, Severely symptomatic brain or bone mets, severe phyciatric disease, etc) 3\) Having difficulties in swallowing, digesting, and absorbing food
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Exploratory study of biomarkers predicting response to nivolumab in non-small-cell lung canceron-small-cell lung cancerJPRN-UMIN000022505Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine200
Recruiting
Not Applicable
Biomarker studies for potentially predicting response to nivolumab in patients with unresectable or recurrent non-small cell lung cancerunresectable or recurrent non-small cell lung cancerJPRN-UMIN000026040Kagoshima University90
Completed
Not Applicable
Investigation of biomarkers for predicting the response to steroids in patients with COPDCOPDJPRN-UMIN000010711Third Department of Internal Medicine, Wakayama Medical University80
Completed
Not Applicable
Identification of biomarkers that predict responsiveness to Dupilumab among severe asthmaJPRN-UMIN000041915ational Hospital Organization Tokyo National Hospital15
Recruiting
Not Applicable
Development of biomarker predicting the response of immunotherapy for patients with urothelial cancer using urine miRNAurothelial cancerJPRN-UMIN000047198Tokyo Medical University120